Wegovy vs Mounjaro: Which Mechanism Suits You?
Ozempic vs Wegovy vs Mounjaro: Understanding the Key Differences
When comparing Ozempic vs Wegovy vs Mounjaro, the first crucial distinction is their licensed purposes. Ozempic contains semaglutide but is licensed exclusively for type 2 diabetes management in the UK — using Wegovy for weight management would be off-label and is not something we can support. Wegovy also contains semaglutide but is specifically licensed by the MHRA for weight management, whilst Mounjaro contains tirzepatide, a dual GIP and GLP-1 receptor agonist also licensed for weight management. The fundamental difference between Wegovy and Mounjaro lies in their mechanisms: Wegovy targets GLP-1 receptors only, whilst Mounjaro's dual-action approach targets both GIP and GLP-1 pathways. This means when evaluating Ozempic vs Wegovy vs Mounjaro for weight management, you're really comparing Wegovy vs Mounjaro, as these are the two MHRA-approved options.
The practical implications of choosing between Wegovy vs Mounjaro extend beyond their mechanisms to dosing schedules and administration. Wegovy follows a five-step dose escalation from 0.25mg to 2.4mg maintenance over 16 weeks, whilst Mounjaro uses six dose levels from 2.5mg to 15mg over a longer titration period. Both are once-weekly injections, but their dose escalation patterns differ significantly. Understanding these differences in the Ozempic vs Wegovy vs Mounjaro comparison helps explain why individual responses vary and why your prescriber's guidance is essential. At EverydayMeds, we stock both Wegovy and Mounjaro to ensure your prescriber can select the most appropriate option based on your clinical assessment and individual circumstances.
Pricing Comparison: Wegovy vs Mounjaro Across All Doses
When evaluating the cost implications of Wegovy vs Mounjaro, transparency in pricing becomes essential for budgeting your weight management journey. Wegovy pricing at EverydayMeds starts with the 0.25mg starter dose at £79.99, progressing through 0.5mg at £94.99, 1mg at £99.99, 1.7mg at £139.99, and reaching the 2.4mg maintenance dose at £209.99. Our bundle options provide convenience for multi-month supply, such as the Intro Duo (0.25mg & 0.5mg) for £169.99 or the Ultimate Stability Trio (three 2.4mg pens) for £649.99. New customers can apply code FIRST40 at checkout, whilst returning customers use DOSE25 to reach these final pricing levels. The structured approach to Ozempic vs Wegovy vs Mounjaro pricing comparison shows that Wegovy offers predictable cost progression through its five-dose escalation schedule.
Mounjaro's pricing structure reflects its different dosing approach, with six available strengths providing more granular dose adjustments compared to Wegovy's five-step protocol. When comparing Wegovy vs Mounjaro costs over a full treatment year, consider that Wegovy reaches maintenance dosing at week 17, whilst Mounjaro's titration may extend longer depending on individual tolerance and prescriber recommendations. Both treatments represent significant investments in your health, which is why EverydayMeds' bundle options help manage the financial commitment whilst ensuring consistent supply. The Ozempic vs Wegovy vs Mounjaro cost analysis ultimately favours having both options available, allowing your prescriber to select based on clinical suitability rather than price alone, with our competitive pricing ensuring affordability across both treatment pathways.
Clinical Evidence: STEP vs SURMOUNT Trial Results
The clinical foundation for choosing between Wegovy vs Mounjaro rests on robust trial evidence, though direct head-to-head studies are limited. Wegovy's efficacy is established through the STEP trial programme, with STEP 1 demonstrating an average weight reduction of approximately 15% at 68 weeks when combined with diet and exercise interventions (Wilding et al., NEJM, 2021). The STEP trials consistently showed that patients taking Wegovy alongside lifestyle modifications experienced significantly greater weight loss compared to placebo groups, with STEP 5 confirming sustained results of approximately 15.2% average weight loss at two years.
Mounjaro's clinical profile emerges from the SURMOUNT trials, which evaluated tirzepatide's dual GIP and GLP-1 receptor agonist mechanism in weight management settings. However, when comparing Ozempic vs Wegovy vs Mounjaro through clinical evidence, it's important to note that trial designs, patient populations, and endpoints varied between studies, making direct percentage comparisons inappropriate. Both Wegovy and Mounjaro demonstrated clinically meaningful weight loss in their respective trials when used alongside reduced-calorie diets and increased physical activity, supporting their MHRA approvals for weight management in eligible patients.
How Wegovy Works: GLP-1 Mechanism Explained
Wegovy's mechanism centres on its role as a GLP-1 receptor agonist, mimicking the action of glucagon-like peptide-1, a natural hormone that regulates appetite and satiety. When you inject Wegovy once weekly, it activates GLP-1 receptors in your brain's appetite control centres, particularly in the hypothalamus, leading to reduced hunger signals and enhanced feelings of fullness after smaller meals. This biological process may help explain why patients in clinical trials experienced reduced food cravings and found it easier to adhere to reduced-calorie diets. The semaglutide in Wegovy has been modified to provide once-weekly dosing through extended half-life properties, maintaining consistent GLP-1 receptor activation throughout the week. Understanding this mechanism helps explain why Wegovy must be used alongside dietary modifications — it enhances your body's natural satiety signals rather than replacing the need for lifestyle changes. The dose escalation protocol from 0.25mg to 2.4mg allows your body to gradually adapt to increased GLP-1 activity, potentially reducing gastrointestinal side effects whilst optimising therapeutic benefits.
EverydayMeds Ordering Process: Assessment to Delivery
Accessing Wegovy or Mounjaro through EverydayMeds begins with our comprehensive 3-minute online clinical assessment, designed to gather the medical history and current health information required for prescriber review. Our qualified prescribers, working within our GPhC-registered pharmacy (#9012878), evaluate each assessment against MHRA licensing criteria, ensuring appropriate prescribing for weight management in eligible patients with BMI ≥30 or BMI ≥27 with weight-related comorbidities. Standard prescriber review takes up to 3 working days, though our express service can provide approval within 24 hours for urgent requirements. Once your prescription is approved, we dispatch your medication via next-day delivery using cold-chain, temperature-controlled logistics to ensure the integrity of your prescription-only medicine throughout transit. This streamlined process eliminates the need for multiple GP appointments whilst maintaining full clinical oversight, ensuring you can begin your weight management journey with either Wegovy or Mounjaro as quickly and safely as possible.
Storage and Practical Considerations: Wegovy vs Mounjaro
Storage requirements represent a practical advantage when comparing Wegovy vs Mounjaro for patients with active lifestyles or frequent travel commitments. Wegovy can be stored at room temperature (below 30°C) for up to 6 weeks once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit, providing significantly more flexibility for holidays, business travel, or situations where refrigeration access is limited. Both treatments require refrigerated storage at 2-8°C before first use and are supplied in pre-filled FlexTouch (Wegovy) or KwikPen (Mounjaro) injection devices, eliminating the need for separate needles or complex preparation. The injection technique is similar for both treatments — a simple subcutaneous injection into the thigh, abdomen, or upper arm once weekly, with injection sites rotated to prevent lipodystrophy. Dose escalation protocols differ significantly: Wegovy's structured 4-week intervals through five doses versus Mounjaro's more flexible titration schedule across six available strengths. Both treatments may cause initial gastrointestinal effects during dose escalation, which typically diminish as your body adapts to the medication, making the gradual dose increases essential for treatment tolerance and long-term success.
Dual Mechanism vs Single Target: Understanding Mounjaro's Advantage
Mounjaro's unique position in the Ozempic vs Wegovy vs Mounjaro comparison stems from its dual GIP and GLP-1 receptor agonist mechanism, representing the first treatment in its class to target both incretin pathways simultaneously. Whilst Wegovy focuses exclusively on GLP-1 receptor activation, Mounjaro adds glucose-dependent insulinotropic polypeptide (GIP) receptor agonism, potentially offering complementary metabolic effects beyond appetite regulation. This dual mechanism may provide additional benefits for glucose metabolism and fat utilisation, though individual responses vary significantly between patients.
The practical implications of choosing between single-target (Wegovy) versus dual-target (Mounjaro) therapy depend largely on your individual metabolic profile, treatment history, and response to dose escalation. Some patients may experience optimal results with Wegovy's focused GLP-1 approach, whilst others may benefit from Mounjaro's broader mechanism of action. The six-dose flexibility of Mounjaro (2.5mg to 15mg) versus Wegovy's five-dose protocol (0.25mg to 2.4mg) also provides different titration options for managing side effects and optimising therapeutic response.
Making Your Choice: Both Available Through EverydayMeds
The decision between Wegovy vs Mounjaro ultimately rests with you and your prescriber, based on your individual medical history, treatment goals, and response to initial therapy. EverydayMeds' unique advantage lies in stocking both treatments through our GPhC-registered pharmacy (#9012878), ensuring your prescriber can select the most clinically appropriate option without supply constraints limiting their choice. Our clinical team can guide you through the Ozempic vs Wegovy vs Mounjaro comparison during your assessment, explaining how Wegovy's established GLP-1 mechanism compares to Mounjaro's innovative dual-target approach. Whether you begin with Wegovy's proven semaglutide formula or Mounjaro's cutting-edge tirzepatide mechanism, both treatments require commitment to the full dose escalation protocol and lifestyle modifications for optimal results. New customers can start their journey with code FIRST40, whilst existing patients continue with DOSE25, ensuring competitive pricing regardless of your chosen treatment path. Visit https://everydaymeds.co.uk/collections/weight-loss to begin your clinical assessment and discover which prescription-only medicine best supports your weight management goals alongside a reduced-calorie diet and increased physical activity.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
